Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

MOMENTA PHARMACEUTICALS, INC. (MNTA) EARNS BUY RATING FROM BREAN CAPITAL

June 5, 2016 Mark Robinson

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s stock had its “buy” rating restated by research analysts at Brean Capital in a research report issued on Wednesday. They presently have a $19.00 price target on the biotechnology company’s stock. Brean Capital’s price objective would indicate a potential upside of 59.80% from the company’s previous close.

http://www.lmkat.com/2016-06-05-momenta-pharmaceuticals-inc-mnta-earns-buy-rating-from-brean-capital/

BTW - JBOG - as DEW stated, please elaborate - it doesn't seem like many onc's are encouraging their patients into the phII portion of the trial.